Quantitative comparison of the neutralizing capacity, immunogenicity and cross-reactivity of anti-TNF-α biologicals and an Infliximab-biosimilar. [electronic resource]
Producer: 20190508Description: e0208922 p. digitalISSN:- 1932-6203
- Adalimumab -- administration & dosage
- Adult
- Aged
- Antibodies, Anti-Idiotypic -- blood
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Neutralizing
- Biological Products -- administration & dosage
- Biosimilar Pharmaceuticals -- administration & dosage
- Certolizumab Pegol -- administration & dosage
- Cross Reactions -- immunology
- Etanercept -- administration & dosage
- Female
- Humans
- Inflammatory Bowel Diseases -- blood
- Infliximab -- administration & dosage
- Male
- Middle Aged
- Tumor Necrosis Factor-alpha -- blood
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.